Benedikt Stegmann
Overview
Explore the profile of Benedikt Stegmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Unterecker S, Hefner G, Baumann P, Grunder G, Bergemann N, Clement H, et al.
Nervenarzt
. 2019 Jul;
90(9):958-960.
PMID: 31309271
No abstract available.
2.
Unterecker S, Hefner G, Baumann P, Grunder G, Bergemann N, Clement H, et al.
Nervenarzt
. 2018 Nov;
90(5):463-471.
PMID: 30446893
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood serum or plasma to optimize pharmacological therapy. TDM is an instrument with which the high interindividual...
3.
Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, et al.
World J Biol Psychiatry
. 2018 Mar;
19(3):162-174.
PMID: 29493375
Objectives: Therapeutic drug monitoring (TDM) combines the quantification of drug concentrations in blood, pharmacological interpretation and treatment guidance. TDM introduces a precision medicine tool in times of increasing awareness of...
4.
Schoretsanitis G, De Leon J, Haen E, Stegmann B, Hiemke C, Grunder G, et al.
Eur Neuropsychopharmacol
. 2017 Nov;
28(1):130-137.
PMID: 29153926
We aimed to explore the differences in the pharmacokinetics of risperidone between oral and long-acting injectable (LAI) formulations using a large database of therapeutic drug monitoring (TDM). Plasma concentrations of...
5.
Kuzin M, Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Grunder G, et al.
Clin Pharmacokinet
. 2017 Sep;
57(6):729-737.
PMID: 28866861
Methods: A therapeutic drug monitoring database contained plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine. We considered three groups: a group of patients who received venlafaxine without confounding medications...
6.
Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Grunder G, Schruers K, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2017 Mar;
76:101-106.
PMID: 28302501
Objectives: To investigate in vivo the effect of low-potency antipsychotics on metabolism of risperidone (RIS). Methods: A therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-OH-RIS...
7.
Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz S, Grunder G, et al.
Br J Clin Pharmacol
. 2017 Feb;
83(8):1668-1675.
PMID: 28160505
Background: Although clinically widespread, scientific evidence for antipsychotic polypharmacy is still limited. Combining different drugs increases the potential for drug-drug interactions, enhancing the risk of adverse drug reactions. We aimed...
8.
Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Grunder G, Paulzen M
Schizophr Res
. 2016 Dec;
185:51-57.
PMID: 27993531
Purpose: To disentangle an association between tobacco smoking, smoking habits and pharmacokinetic patterns such as plasma concentrations of risperidone (RIS), its active metabolite 9-hydroxyrisperidone (9-OH-RIS) and the active moiety, AM,...
9.
Schoretsanitis G, Haen E, Grunder G, Stegmann B, Schruers K, Hiemke C, et al.
J Clin Psychopharmacol
. 2016 Nov;
36(6):554-561.
PMID: 27811552
Background: The combination of anticonvulsant mood stabilizers with antipsychotic drugs may lead to clinically relevant drug-drug interactions. The objective of the study was to identify pharmacokinetic interactions of different mood...
10.
Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Grunder G, et al.
Eur Arch Psychiatry Clin Neurosci
. 2016 Oct;
267(4):325-333.
PMID: 27695935
The purpose of this study was to disentangle an association between plasma concentrations of risperidone (RIS), its active metabolite 9-hydroxyrisperidone (9-OH-RIS) and the active moiety, AM (RIS + 9-OH-RIS), and...